As part of its historical documentary “How Seattle Changed the World,” KOMO TV highlights Seattle innovators as well as the CoMotion at University of Washington incubator program for start-up companies. Anavasi Diagnostics® is honored to have been included in this feature (at approximately 48.50 in the video).

Chief Medical Officer Michael Blaivas, MD, MBA, FACEP, FAIUM, talks with FOX 5 DC about staying healthy during the holidays and what to do if you test positive. As molecular Covid tests are more accurate than antigen tests, Mike recommends getting one performed before your get-together to ensure you are negative.

While molecular tests (such as the AscencioDx), due to their high accuracy and sensitivity, are the gold standard for diagnosing Covid, at-home rapid antigen tests can be useful in some circumstances. This article details its recommendations.

Innovation is just one of the things we excel at. Being GREEN is another. We are happy to share that in Fast Company's Next Big Things in Tech awards for 2022, Anavasi Diagnostics® received an honorable mention in their Small and Mighty category.

In an article for Pharmacy Times, Anavasi Diagnostics® Chief Medical Officer Michael Blaivas, MD, MBA, FACEP, FAIUM discusses the ever-changing Covid variants and how some mutations may make them resistant to certain treatments.

Anavasi Diagnostics® is pleased to announce the election of three new outside members to its Board of Directors,

Barry Lutz, co-founder and CSO with Anavasi Diagnostics®, shares things he learned as part of a startup firm with GeekWire.

If you have not yet contracted COVID, you may be a super dodger. Michael Blaivas, MD, MBA, FACEP, FAIUM discusses this topic, new variants and other viruses with Eat This, Not That!

University of Washington professor Barry Lutz, a principal investigator with the Seattle Flu Study and Co-Founder & Chief Scientific Officer with Anavasi Diagnostics®, discusses the future landscape of at-home tests with NEO.LIFE.

Suffering from a loss of your sense of taste or smell as a result of COVID? In this HealthDigest article, Michael Blaivas, MD, MBA, FACEP, FAIUM offers some suggestions for coping with it.

Michael Blaivas, MD, MBA, FACEP, FAIUM discusses the CDC's latest COVID guidelines as well as testing options in his most recent article for Eat This, Not That!

While we are no longer in a “pandemic” state per Merriam-Webster’s Medical Dictionary’s definition of the word, we are not quite out of the woods when it comes to COVID according to Mike Blaivas.

School is back in session but no one told COVID the pandemic is supposed to be over. The latest COVID news and how to stay safe can be found in this article by practicing ER doctor Michael Blaivas, MD, MBA, FACEP, FAIUM.

What are some of the potential dangers of contracting COVID while pregnant? Learn more in this HealthDigest article featuring ER physician Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer at Anavasi Diagnostics®.

Even though COVID-19 can spread equally in warm and cold temperatures, weather can still influence infection rates, as activities can shift from outdoor to indoor settings with the weather, affecting one's proximity to potentially infected individuals.

The latest article by Anavasi Diagnostics’ Chief Medical Officer and practicing ER physician Mike Blaivas examines the current COVID landscape.

The latest Omicron variant BA 2.75 has now emerged in the US, and although its traits are similar to BA.5, it is too early to tell if it will become a dominant strain. Since new variants are constantly emerging, rapid antigen tests may not be keeping up with them, making it difficult for individuals to know if their results are accurate.

Typically, flu, rhinoviruses, and adenoviruses peak in the winter, but medical professionals are seeing a spike this summer. Several possibilities may account for the rise, including COVID-19's introduction and its many subvariants, as well as multi-plex testing, which was not previously a standard summer test.

Dr. Blaivas discusses BA.5, the latest variant of COVID, and how easy it is to transmit, even in outdoor gatherings.

Currently, the BA.4 and BA.5 variants account for 70% of all COVID cases in the U.S. During an interview with Parade Magazine, Chief Medical Officer and Emergency Room physician Michael Blaivas discusses these variants and their symptoms.

Planning ahead for COVID when traveling is key. This article offers six recommendations about how to prepare in advance for a possible COVID infection while traveling.

In this article, Dr. Blaivas discusses why Paxlovid should be started early in COVID infection, how it interacts with other drugs, and the need for testing.

What can you expect after taking Paxlovid? Dr. Blaivas discusses this topic with Health Digest.

"Realistically, you need to test until you get a negative result," according to Dr. Blaivas, when completing a course of Paxlovid for a COVID infection.

Chief Medical Officer Dr. Blaivas discusses the latest Omicron variants BA.4 and BA.5.

Scott Robitaille announced as new Vice President of Sales and Marketing at Anavasi Diagnostics,

According to Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer at Anavasi Diagnostics® in his byline for Eat This, Not That!, regular testing is key to stopping the spread of COVID.

In the fight against COVID, at home tests are a useful tool, however because the majority of these results are not reported, healthcare experts believe we have falsely low infection numbers. Michael Blaivas, Chief Medical Officer with Anavasi Diagnostics, discusses the importance of reporting rapid test results and how to do so.

Chief Medical Officer, Michael Blaivas, MD, MBA, FACEP, FAIUM, spoke to Fox News Media about antigen testing following an FDA announcement regarding two counterfeit COVID at-home tests in the United States.

Anavasi Diagnostics Chief Medical Officer Michael Blaivas recently spoke with BestLife Magazine about COVID testing for travelers. "Some airlines and countries have realized that antigen type tests are not as accurate as desired and have progressed to allowing molecular or PCR type testing only," stated Dr. Blaivas.

In a recent interview with Fortune, Michael Blaivas, Chief Medical Officer of Anavasi Diagnostics® discussed similarities between seasonal allergies and COVID. Rather than trying to distinguish those symptoms by yourself, he suggested taking a COVID test.

This article, written by Anavasi Diagnostics® Diagnostics Chief Medical Officer, Michael Blaivas, MD, MBA, FACEP, FAIUM, explores how people are catching COVID and why it is crucial for providers to have access to rapid, molecular diagnostic tests (such as the AscencioDx) in point-of-care settings to detect and treat COVID.

Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer for Anavasi Diagnostics®discusses Omicron and its subvariants with Health.com.

Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer for Anavasi Diagnostics® recently discussed COVID virus mutations and the resulting emergence of two new COVID sub-variants with Healthline Media.Description goes here

Anavasi Diagnostics was recently mentioned in this article by Wellspring Worldwide.

A new variant, called "Stealth Omicron" or BA.2, has recently emerged. “Despite the name ‘stealth,’ it can be detected by molecular tests, and we have evaluated if the Anavasi Diagnostics® Covid test will detect BA.2 and it will,” according to Anavasi Diagnostics’ Chief Medical Officer Michael Blaivas, MD, MBA, FACEP, FAIUM.

Nelson Patterson, CEO of Anavasi Diagnostics®, had the pleasure of speaking last month at the Life Science Intelligence Emerging MedTech Conference in Dana Point, California.

GenomeWeb interviews Anavasi Diagnostics® Chief Executive Officer Nelson Patterson as he discusses its revolutionary technology and its plans for the future.

We are in the news again. Clinical Lab Products (CLP) has published a follow up article on Anavasi Diagnostics regarding our company's submission of clinical data to the FDA to request an EUA for our AscencioDx® COVID 19 Molecular Diagnostic System.

Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer for Anavasi Diagnostics®, recently spoke with Parade Magazine regarding the new Deltacron variant. With emerging variants, Dr. Blaivas indicated that “most molecular tests should have no difficulty detecting the virus, and this is critical to stopping the spread of the virus”.

COVID-19 demonstrated the need for affordable and accessible Molecular Diagnostic quality testing for infectious diseases and led to the emergence of new revolutionary diagnostics. In the early days of SARS, Anavasi Diagnostics had a great molecular diagnostic system in development for the detection of HIV and Flu, so it shifted its R & D efforts to the detection of COVID-19.

Anavasi Diagnostics Chief Medical Officer Michael Blaivas, MD, MBA, FACEP, FAIUM discusses the effects of extreme temperature changes on rapid COVID-19 tests.

Deliberately “getting infected with Omicron is actually a bit like playing Russian roulette” according to Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer with Anavasi Diagnostics, makers of the AscencioDx™ Molecular Diagnostic System, in an interview last week with First for Women.

The Wall Street Journal Pro Venture Capital recently spoke with Anavasi CEO Nelson Patterson about the potential uses for the AscencioDx™ COVID 19 Molecular Diagnostic System and how it intends to apply for Emergency Use Authorization in the coming weeks.

What is an endemic? Parade Magazine recently spoke with Dr. Michael Blaivas, an emergency room physician and Chief Medical Officer of Anavasi Diagnostics, about this very topic.

Should we just catch Omicron and be done with it? Michael Blaivas, MD, MBA, FACEP, FAIUM, Anavasi Diagnostics' Chief Medical Officer and practicing emergency room physician, recently spoke with PureWow about this very topic.

Is it Flurona? Flurona is the latest buzzword which is derived from... As part of an interview with Allure Magazine, Michael Blaivas, Chief Medical Officer of Anavasi Diagnostics, discusses the possibility of being infected with influenza AND COVID-19 and how doctors are testing for both to aid in their treatment decisions.

Anavasi Diagnostics appoints COO, CCO and CFO to executive team.

Interview with Dr. Barry Lutz.

Anavasi Diagnostics announces appointments to the executive team.

Becker's Hospital Review published an in-depth interview with Michael Blaivas, MD, MBA, FACEP, Chief Medical Officer for Anavasi Diagnostics, regarding the challenges associated with Omicron testing today.

Anavasi Diagnostics' Chief Medical Officer, Michael Blaivas, MD, MBA, FACEP, FAIUM, was recently interviewed by WebMD Health News for their article, “Swab Nose, Throat, or Both for COVID-19 Rapid Tests.”

USA Today Online interviewed Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer of Anavasi Diagnostics regarding the use of throat swabs when a consumer would use an at-home COVID test amid the overwhelming Omicron variant outbreak and expanded use of these home Tests.

Bloomberg Business Radio recently interviewed Michael Blaivas, MD, MBA, FACEP, FAIUM, Chief Medical Officer for Anavasi Diagnostics about the need for more testing for the omicron variant.